Data on the use of rituximab in treating patients with systemic lupus erythematosus (SLE) has been far from clear; 2 randomized controlled trials of rituximab in patients with SLE failed to meet their primary endpoints, while open-label trials have reported the drug’s efficacy in this indication.
Despite advances in the treatment of systemic lupus erythematosus (SLE) in recent years, a number of patients are refractory to conventional immunosuppressive therapies, or require unacceptably high doses of glucocorticoids for adequate disease control. Because B cells play a role in SLE, rituximab has been proposed as a potential treatment for SLE. However, data on the use of rituximab in this indication has been far from clear; 2 randomized controlled trials of rituximab in patients with SLE failed to meet their primary endpoints, while open-label trials have reported the drug’s efficacy in patients with refractory SLE.
In a paper newly published in Rheumatology, researchers used the British Isles Lupus Assessment Group Biologics Register to describe the baseline characteristics of patients in the United Kingdom who were initiating biologic therapy during the first 5 years of the register, and to evaluate the early efficacy of rituximab treatment in the first 6 months.
Patients (n = 270) with SLE who were aged 5 years or older and had started a new biologic therapy in the past 12 months were included. Patients were followed up at 3, 6, and 12 months, then annually for at least 2 years. Most patients were women (92%), the mean disease duration was 8.4 years (standard deviation, 8.7 years), and the majority (60%) were white. Most (74%) had 1 or more comorbidity. In total, 91% of patients were taking antimalarial drugs, and 93% were taking glucocorticoids. Among patients who started a biologic, 97% initiated treatment with rituximab.
A total of 178 patients who received rituximab completed baseline and 6-month assessments. At 3 months, 91 (51%) patients had responded to rituximab treatment, and at 6 months, 88 (49%) had responded. Another 9 (5%) patients—all of whom had required unacceptably high levels of steroids—experienced no worsening in disease control over 6 months after treatment with rituximab, and were able to reduce their steroid dosages.
A major clinical response was achieved by 33 (18.4%) patients. After rituximab treatment, disease activity increased in 26 (15%) patients at 3 months and 33 (19%) patients at 6 months, however.
There were 185 infections reported in 82 (30%) of patients, with respiratory and urinary tract infections most commonly reported.
More work will be necessary to identify predictors of response to rituximab, but, say the authors, “It is notable that almost one in five patients achieved a major clinical response at 6 months.” The authors conclude that rituximab appears to be safe and efficacious in treating refractory SLE, and that as additional biologic agents become available, inclusion of these agents in the register will allow for real-world comparison of treatments in identifying which patients will benefit from biologic therapies.
Reference
McCarthy EM, Sutton E, Nesbit S, et al. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology. 2018;57(3):470-479. doi: 10.1093/rheumatology/kex395.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
September 16th 2024Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.
Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA
September 14th 2024A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product (Remicade) or another biologic or targeted synthetic disease-modifying antirheumatic drug.